Search for a trial

Prospective registry of management and outcome of bleeding complications in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs)

Primary objectiveTo assess the outcome of NOAC associated bleeds and emergency invasive surgery or procedures. Secondary objectives1) To describe the treatment of patients presenting with NOAC associated bleeding2) To evaluate the current…

A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 - 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting

See section 2.2 of the protocol.The main objective of this study is to compare a DAT regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg DE-DAT) and 150mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (…

Dutch randomized trial comparing Ultrasound-accElerated Thrombolysis with standard dose Urokinase versus half dose Urokinase for thrombo-embolic infra-inguinal arterial disease (DUET II)

To demonstrate that the use of US-accelerated catheter-derived thrombolysis in patients with recently (less than 7 weeks) thrombosed infra-inguinal bypass grafts or native arteries with half the dose urokinase (50.000 IU/h) will significantly reduce…

Anti-Xa activity after a reduced therapeutic dose of nadroparin in patients with renal impairment using a dosage guideline of the Dutch Federation of Nephrology

The primary objective of this study is to determine the anti-Xa activity after a reduced therapeutic dose of nadroparin in patients with an eGFR < 60 ml/min in comparison with the anti-Xa activity after a standard therapeutic dose of…

Multi Center Clinical trial of endovascular treatment of acute ischemic stroke in the Netherlands.

The primary objective of this study is to estimate the effect of endovascular treatment on overall functional outcome after acute ischemic stroke of less than six hour duration, in patients with a symptomatic anterior circulation IAO. The secondary…

INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL - IMS III
A phase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase®/Actilyse®) alone when initiated within three hours of acute ischemic stroke onset.

The primary objective of the trial is to determine if ischemic stroke subjects with a baseline NIH Stroke Scale Score (NIHSSS] >= 10 (8-9 with positive CTA) treated with recombinant tissue plasminogen activator (rt-PA; [Alteplase recombinant…

Dutch randomized trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thrombo-embolic infra-inguinal disease.

Te demonstrate that the use of US-accelerated catheter-derived thrombolysis in patients with recently (between 1 and 7 weeks) thrombosed infra-inguinal bypass grafts or native arteries will significantly reduce (at least 12 hours) therapy time…

Pharmacokinetics and *dynamics of Dabigatran Etexilate and Rivaroxaban in patients requiring PArenteral Nutrition (the PDER PAN study)

The aim of this phase I study is to assess the extent of intestinal absorption of rivaroxaban and dabigatran etexilate in adult patients with short bowel syndrome and treated with long-term TPN.

Thrombolysis Or Anticoagulation for Cerebral venous Thrombosis

The objective of this study is to determine the clinical efficacy of endovascular thrombolytic treatment (ET) as compared to standard treatment (any therapeutic heparin regimen) in patients with proven cerebral venous sinus thrombosis and a high…

The Efficacy of Pro- and Anticoagulant Therapy in Plasma of Patients with Cirrhosis undergoing Orthotopic Liver Transplantation

To investigate the in vitro effect of both pro- and anticoagulation therapy on thrombin generation by Calibrated Automated Thrombography in plasma from patients with cirrhosis undergoing liver transplantation.

The treatment of venous thromboembolism with edoxaban in patients with cirrhosis, a pharmacokinetic study.

To assess the safety and effect of edoxaban in Chil-Pugh B cirrhosis.

Understanding Neuromodulation of the Stroke Brain

The objective of this study is to determine whether contralesional cTBS treatment modulates the interhemispheric imbalance in excitability or local or transcallosal inhibitory processes in the motor network of a population of stroke patients…

PEERLESS study

The primary study objective is to compare the clinical outcomes of patients treated with the FlowTriever System versus Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute intermediate-high-risk pulmonary embolism (PE).

Dual thrombolytic therapy with mutant pro-urokinase (m-pro-urokinase, HisproUK) and low dose alteplase for ischemic stroke

To test the safety and preliminary efficacy of a dual acute thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV infusion of m-pro-urokinase against usual treatment with IV alteplase in patients presenting…

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE

This study has been transitioned to CTIS with ID 2024-513992-42-00 check the CTIS register for the current data. The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through…

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and
bleeding in patients with cancer associated VTE (ASTER)

This study has been transitioned to CTIS with ID 2023-509569-19-00 check the CTIS register for the current data. The primary objective of this study is to assess whether abelacimab is non-inferior to apixaban for preventing VTE recurrence at 6…

Brain-STimulation for Arm Recovery after Stroke

To determine the therapeutic effect of contralesional cTBS on recovery of function of the paretic arm, at 3 months after ischemic stroke

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (probe) study - the Caravaggio study

The aim of this study is to assess whether oral apixaban in non-inferior to the subcutaneous LMWH dalteparin for the treatment of newly diagnosed proximal DVT and/or PE in patients with cancer.

A Phase 3b, prospective, randomized, open-label, blind evaluator (PROBE) study evaluating the efficacy and safety of LMWheparin/edoxaban versus dalteparin in venous thromboembolism associated with cancer

The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH compared with dalteparin for theprevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects…

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist- based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement (ENTRUST_AF PCI)

The primary objective is to compare a 12-month antithrombotic regimen of edoxaban in combination with clopidogrel or another P2Y12 antagonist against a regimen of a vitamin K antagonist (VKA) in combination with clopidogrel or another P2Y12…